Subjects with Stage III resectable melanoma will receive adjuvant therapy, nivolumab or ipilimumab plus nivolumab, based on whether a pathologic complete response (CR) or near CR (less than 10% viable tumor cells) is achieved with one dose of nivolumab in the neoadjuvant setting followed by surgery.

You may be eligible for this study if you meet the following criteria:

• Conditions: oncology, cancer
• Age: - 99 Years
• Gender: All